Richard A. Lewis

FDA Is Open To The Idea Of Possible Regulatory Flexibility For Cell And Gene Therapies On A Case-by-Case Basis…Where Appropriate

What To Expect When You Are Expecting…A Government Shutdown

FDA Issues "Cliffs Notes"-style Guidance On Cell And Gene Therapy; What CMC Questions Did They Answer? (Part 2)

Lots Of FDA Guidance, But Few Drug Manufacturing "Remote Interactive Evaluations" (We Would Call Them "Virtual Inspections")

Welcome To SRP-RMT – Standardization Comes To Regenerative Medicine Therapies?